Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
To own Recursion, you have to believe its AI driven platform can turn early clinical assets and pharma collaborations into durable, less partnership dependent revenue, while managing heavy cash burn.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results